human cxcl13 quantikine elisa kit (R&D Systems)
Structured Review

Human Cxcl13 Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 82 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cxcl13/Human+CXCL13%2FBLC%2FBCA-1+Quantikine+ELISA+Kit/pmc13106335-76-7-13
Average 95 stars, based on 82 article reviews
Images
1) Product Images from "CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases"
Article Title: CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases
Journal: Frontiers in Immunology
doi: 10.3389/fimmu.2026.1804103
Figure Legend Snippet: CXCL13 mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
Techniques Used: Expressing, Whisker Assay, Standard Deviation
Figure Legend Snippet: CXCL13 immunohistochemical expression in skin biopsies from Sézary syndrome, mycosis fungoides and inflammatory skin diseases. Representative immunohistochemical staining for CXCL13 in skin lesions from patients with Sézary syndrome [SS; (A) ] and mycosis fungoides [MF; (B) ], showing CXCL13 expression in endothelial cells and neoplastic lymphocytes infiltrating the dermis, frequently displaying a dot-like staining pattern. In atopic dermatitis [AD; (C) ], psoriasis [PS; (D) ], eczema [EC; (E) ] and healthy donor skin [HD; (F) ], CXCL13 immunoreactivity is mainly confined to endothelial cells and scattered non-neoplastic lymphocytes. Sections were counterstained with haematoxylin. Original magnification: ×10; inserts ×40.
Techniques Used: Immunohistochemical staining, Expressing, Staining
Figure Legend Snippet: Plasma CXCL13 levels and diagnostic performance in Sézary syndrome. (A) Box-and-whisker plots showing individual plasma CXCL13 concentrations in patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS), eczema (EC) and healthy donors (HD). Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. (B) Plasma CXCL13 concentrations in MF patients stratified according to disease stage at sampling (stage IB/IIA vs . advanced stages IIB and III). Statistical significance was assessed using the Mann–Whitney U test. (C) Receiver operating characteristic (ROC) curve analysis evaluating the ability of plasma CXCL13 to discriminate SS patients from all non-SS individuals (MF, AD, PS, EC and HD). The red cross indicates the selected cut-off value (151.1 pg/mL) maximising sensitivity (87%) and specificity (88%). (D) Box-and-whisker plots showing individual plasma CXCL13 concentrations in SS (right) and non-SS (left) patients. The dotted line indicates the ROC-derived cut-off value. Statistical significance was assessed using the Mann–Whitney U test. ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05.
Techniques Used: Clinical Proteomics, Diagnostic Assay, Whisker Assay, Sampling, MANN-WHITNEY, Derivative Assay
Related Articles
Cell Culture:Article Title: Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13. Article Snippet: Background: We have previously shown that the homeostatic chemokine CXCL13 is up-regulated in monocytes in atherosclerosis, mediating anti-apoptotic and anti-inflammatory effects.. Objective: To investigate the regulation of CXCL13s receptor, CXCR5.. Methods/patients: In vitro studies in THP-1 and primary monocytes and studies of CXCR5 expression in thrombus material obtained at the site of plaque rupture during myocardial infarction (MI). Recombinant:Article Title: Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13. Article Snippet: Background: We have previously shown that the homeostatic chemokine CXCL13 is up-regulated in monocytes in atherosclerosis, mediating anti-apoptotic and anti-inflammatory effects.. Objective: To investigate the regulation of CXCL13s receptor, CXCR5.. Methods/patients: In vitro studies in THP-1 and primary monocytes and studies of CXCR5 expression in thrombus material obtained at the site of plaque rupture during myocardial infarction (MI). Article Title: CXCL13 Promotes Proliferation of Mesangial Cells by Combination with CXCR5 in SLE Article Snippet: Human renal mesangial cells (HRMCs) were purchased from JENNIO Biological Technology and cultured in RPMI-1640 medium (HyClone) with 10% fetal bovine serum (FBS, Gibco) at 37°C in 5% CO 2 . .. Cells were treated with recombinant Article Title: Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis Article Snippet: Cells were directly sorted into 100μl of freshly prepared media (HBSS containing 10% FBS) at 4°C and transferred into the top well of a Corning HTS 24-well transwell plate. .. Bottom chambers of transwell plates were loaded with 600μl of either media alone, for controls, or media and 500ng/ml of recombinant Article Title: CXCL13 Promotes Proliferation of Mesangial Cells by Combination with CXCR5 in SLE. Article Snippet: Human renal mesangial cells (HRMCs) were purchased from JENNIO Biological Technology and cultured in RPMI-1640 medium (HyClone) with 10% fetal bovine serum (FBS, Gibco) at 37∘C in 5% CO 2 . .. Cells were treated with recombinant Article Title: TNFR2 Signaling Enhances Suppressive Abilities of Human Circulating T Follicular Regulatory Cells. Article Snippet: .. In total, 50 ml of suspended cells was placed in the upper chamber of Transwell Polycarbonate Membrane Inserts (5-mm pore, 96 wells; Corning, Corning, NY), and the lower chambers were filled with 150 ml of RPMI-1640 medium containing 10% with recombinant Incubation:Article Title: Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13. Article Snippet: Background: We have previously shown that the homeostatic chemokine CXCL13 is up-regulated in monocytes in atherosclerosis, mediating anti-apoptotic and anti-inflammatory effects.. Objective: To investigate the regulation of CXCL13s receptor, CXCR5.. Methods/patients: In vitro studies in THP-1 and primary monocytes and studies of CXCR5 expression in thrombus material obtained at the site of plaque rupture during myocardial infarction (MI). Enzyme-linked Immunosorbent Assay:Article Title: Homing defects of B cells in HIV-1 infected children impair vaccination responses. Article Snippet: .. The Clinical Proteomics:Article Title: Homing defects of B cells in HIV-1 infected children impair vaccination responses. Article Snippet: .. The Membrane:Article Title: TNFR2 Signaling Enhances Suppressive Abilities of Human Circulating T Follicular Regulatory Cells. Article Snippet: .. In total, 50 ml of suspended cells was placed in the upper chamber of Transwell Polycarbonate Membrane Inserts (5-mm pore, 96 wells; Corning, Corning, NY), and the lower chambers were filled with 150 ml of RPMI-1640 medium containing 10% with recombinant Immunohistochemical staining:Article Title: Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid. Article Snippet: CXCL13 recruits CXCR5 follicular helper T (Tfh) cells in inflammatory lesions to develop secondary lymphoid organs.. Tfh cells activate B cells to produce antibodies during humoral immune responses.. Indeed, as previous reports suggested, CXCR5 cell numbers were increased in the peripheral blood of bullous pemphigoid (BP) patients when compared with healthy donors, and the ratio of CXCR5 cells was positively correlated with the anti-BP180-NC16A titers. Immunohistochemistry:Article Title: Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid. Article Snippet: CXCL13 recruits CXCR5 follicular helper T (Tfh) cells in inflammatory lesions to develop secondary lymphoid organs.. Tfh cells activate B cells to produce antibodies during humoral immune responses.. Indeed, as previous reports suggested, CXCR5 cell numbers were increased in the peripheral blood of bullous pemphigoid (BP) patients when compared with healthy donors, and the ratio of CXCR5 cells was positively correlated with the anti-BP180-NC16A titers. Staining:Article Title: Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid. Article Snippet: CXCL13 recruits CXCR5 follicular helper T (Tfh) cells in inflammatory lesions to develop secondary lymphoid organs.. Tfh cells activate B cells to produce antibodies during humoral immune responses.. Indeed, as previous reports suggested, CXCR5 cell numbers were increased in the peripheral blood of bullous pemphigoid (BP) patients when compared with healthy donors, and the ratio of CXCR5 cells was positively correlated with the anti-BP180-NC16A titers. |
![( A ) Expression of CD27 and IgD on CD19 + B cells. Right: Percentage of IgD + CD27 − naïve B cells and IgD − CD27 − DN B cells. ( B ) Expression of CD27 and CD38 on CD19 + B cells. Right: Percentages of CD27 hi CD38 hi ASCs and CD27 + CD38 − memory B cells. ( C ) Expression of CD138 on CD27 hi CD38 hi ASCs. Right: Percentage of CD138 + ASCs and CD138 − ASCs. ( D ) Expression of CD11c and CD21 on CD19 + B cells. Right: Percentage of CD11c + CD21 − CD19 + B cells. [(A) to (D)] HC ( n = 63), irAE ( n = 33), RAC ( n = 46), and ICI ( n = 20). ( E to G ) GSEA was performed on the B cells between irAE and ICI. (E) Significantly enriched pathways in B cells from irAE and ICI. GSEA plots of IFN-α and IFN-γ response (F), and oxidative phosphorylation (G). ( H ) The volcano plots of the citrullinated or noncitrullinated relative IgG or IgM isotype autoantigen levels comparing RA versus HC, irAE versus ICI, irAE versus HC, or irAE versus RA. The autoantigens were labeled when P < 0.01. TNF-α reactivities resulted from the administration of anti–TNF-α therapy for the treatment of RA. ( I ) Immunoglobulin isotype levels in the plasma were measured by multiplex assay. HC ( n = 22), irAE ( n = 34), RAC ( n = 46), and ICI ( n = 26). ( J ) CXCL13 levels in the plasma were measured <t>by</t> <t>enzyme-linked</t> immunosorbent assay (ELISA). HC ( n = 20), irAE ( n = 34) RAC ( n = 47), and ICI ( n = 23). ( K ) B-cell activating factor (BAFF) levels in the plasma were measured by multiplex assay. HC ( n = 21), irAE ( n = 34), RAC ( n = 47), and ICI ( n = 18). Data in graphs represent mean ± SEM. Significance was tested by one-way ANOVA [(A) to (D) and (I) to (K)] and logistic regression (H). [(A) to (D) and (F) to (K)] ICI, ICI control.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_1753/pmc13041753/pmc13041753__sciadv.aea4262-f3.jpg)
